A Phase 1 interventional study of Adalimumab 100 MG/ML [Humira] and AVT02 100MG/ML in Healthy Volunteers, sponsored by Alvotech Swiss AG. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-18.
Sponsored by Alvotech Swiss AG · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Adalimumab is an immunosuppressive drug that belongs to the family of anti-TNF agents. It contains a monoclonal antibody produced by biotechnology. It is designed to bind to tumor necrosis factor (TNF), a substance that is involved in several auto-immune processes. By binding to TNF, adalimumab blocks its activity, reducing the severity of various chronic inflammatory diseases including Rheumatoid Arthritis, Plaque Psoriasis and others.
Often, the high cost of biologic products may preclude access to the treatment to a big portion of the population worldwide. A biosimilar product that provides comparable safety and efficacy at more affordable cost would fulfill a broader medical need.
Humira has been available on the market for several years. Recently, a higher concentration (100 mg/mL) formulation has been introduced in major markets. Alvotech is developing AVT02, that is a proposed biosimilar of adalimumab containing high concentration (100 mg/mL) of active ingredient.
The objective of this clinical trial is to assess the similarity of AVT02 (100 mg/mL) with Humira (100 mg/mL), in terms of tolerability, safety (including immunogenicity) and compare the pharmacokinetics in healthy volunteers.
Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single subcutaneous injection of 40 mg of AVT02 (100MG/ML)
Drug: AVT02 100MG/ML
Single subcutaneous injection of 40 mg of Adalimumab (100MG/ML) \[HUMIRA\]
Drug: Adalimumab 100 MG/ML [Humira]
Drug page: Adalimumab
prefilled syringe at a concentration of 100MG/ML and delivering 40MG of adalimumab, as a single dose on day 1 day 1
Drug page: Adalimumab
prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1
Change from baseline blood pressure at 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing
Measurement of blood pressure (systolic and diastolic in mm Hg)
Time frame: Predose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing
Change from baseline heart rate at 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing
Measure of heart rate (beats per minute)
Time frame: Predose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing
Change from baseline body temperature at 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing
Measurement of oral temperature (Celsius degree)
Time frame: Predose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing
Change from baseline electrocardiogram at 1, 2, 5, 9, 64 days post dosing
Analysis of 12-lead electrocardiogram
Time frame: Predose and 1, 2, 5, 9, 64 days post dosing
Change from baseline red blood cells at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure red blood cells count, (unit/mm3)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline haemoglobin at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure haemoglobin (g/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline white blood cells at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure white blood cells count, (unit/mm3)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline platelets at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure platelets count, (unit/mm3)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline blood gamma glutamyl transferase at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure gamma glutamyl transferase (UI/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline blood aspartate aminotransferase at 2, 3, 5, 9, 64 days post
Blood collection to measure aspartate aminotransferase (UI/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline blood alanine aminotransferase at 2, 3, 5, 9, 64 days post
Blood collection to measure alanine aminotransferase (UI/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline blood potassium at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure potassium (mmol/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline blood sodium at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure sodium (mmol/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline blood calcium at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure calcium (mmol/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline blood phosphate at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure phosphate (mmol/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline blood chloride at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure chloride (mmol/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline blood bicarbonate at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure bicarbonate (mmol/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline blood creatinine at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure creatinine (micromol/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline blood bilirubin at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure Bilirubin (micromol/L)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline international normalised ratio at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure international normalised ratio
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline prothrombin time at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure prothrombin time (sec)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline partial prothrombin time at 2, 3, 5, 9, 64 days post dosing
Blood collection to measure partial prothrombin time (sec)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline activated partial thromboplastin time at 2, 3, 5, 9, 64 days post
Blood collection to measure activated partial thromboplastin time (sec)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline thrombin time at 2, 3, 5, 9, 64 days post
Blood collection to measure thrombin time (sec)
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline urine leucocytes at 2, 3, 5, 9, 64 days post dosing
Urine sample collection to measure leucocytes
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline urine glucose at 2, 3, 5, 9, 64 days post dosing
Urine sample collection to measure glucose
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Change from baseline urine protein at 2, 3, 5, 9, 64 days post dosing
Urine sample collection to measure protein
Time frame: Predose and 2, 3, 5, 9, 64 days post dosing
Area under the plasma concentration-time curve (AUC)
Venous blood samples will be collected for measurement of Area under the plasma concentration-time curve (AUC) of AVT02 and EU Humira
Time frame: Over 64 days
Maximum serum concentration
Venous blood samples will be collected for measurement of serum concentration of AVT02 and EU Humira
Time frame: Over 64 days
Time to maximum serum concentration
Evaluation of time to maximum plasma concentration (Tmax) of AVT02 and Humira.
Time frame: Over 64 days
Terminal half-life
Evaluation of terminal elimination half-life (T1/2) of AVT02 and Humira
Time frame: Over 64 days
Volume of distribution
Evaluation of volume of distribution during the elimination phase (Vz) of AVT02 and Humira
Time frame: Over 64 days
Clearance
Evaluation of total plasma clearance (CL) of AVT02 and Humira
Time frame: Over 64 days
Incidence and titer of anti-drug antibodies to adalimumab
A blood sample will be collected to measure antibodies to AVT02 and Humira
Time frame: 15, 29 and 64 days after dosing
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2018 to primary completion in Aug 2018, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
Alvotech Swiss AG